Anbio Biotechnology (NNNN)
Designs and distributes diagnostic products for laboratory, point-of-care, and home-use settings.
Something off on this page? Send us feedback.
Diagnostic products are designed across multiple testing platforms, made by outside manufacturers, and distributed for laboratory, point-of-care, and home-use settings. A single operating segment covers Europe, APAC, the Americas, and Africa.
Built around FIA, CLIA, RT-PCR, LFIA, LAMP, and Dry Chemistry, the in-vitro diagnostic product suite serves laboratory, point-of-care, and home-use settings. Products are designed internally, produced by original-equipment manufacturers, and distributed as finished diagnostics.
Commercial coverage spans Europe, APAC, the Americas, and Africa within a single operating segment. Research and development, product design, marketing, operations, and administration are shared across the suite, while product-sale revenue is generally recognized when control transfers at shipment.
All purchases are concentrated with two suppliers, and products are subject to health-care and product requirements in the jurisdictions where they are sold. Class B shares were structured to preserve holders’ voting influence.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $11.9M · Total debt $0 · Total assets $30.2M · Shareholders' equity $30.2M
- Revenue
- $4.7M
- Operating income
- $2.8M
- Net income
- $3.0M
No dividends on record.
| Institutions | 0.16% | 71.9K shares | |
|---|---|---|---|
| 12 holders · as of Jun 30, 2026 | |||
| Other | 99.84% | 43.82M shares | |
| remainder | |||
43.89M company shares as of Sep 13, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Geode Capital Management, LLCInstitution | 0.06% | 26,736 | as of Jun 30, 2026 |
Bank of America Corp /DE/Institution | 0.03% | 13,419 | as of Jun 30, 2026 |
BNP Paribas Arbitrage, SNCInstitution | 0.03% | 11,800 | as of Jun 30, 2026 |
Marshall Wace, LLPInstitution | 0.03% | 11,502 | as of Jun 30, 2026 |
Morgan StanleyInstitution | 0.02% | 7,231 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Abbott
Broad IVD rival across laboratory, molecular, rapid and point-of-care testing
- Danaher
Global molecular-diagnostics rival through Cepheid
- QuidelOrtho
Direct rival in point-of-care and molecular diagnostics
- BD
Rival in clinical microbiology, molecular and rapid testing
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Anbio Biotechnology | $5.66 | −0.27% | $249.3M | — | — | — | — |
| Abbott | $104.18 | +1.17% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| Danaher | $220.82 | +2.31% | $151.67B | 38.3 | 25.0 | 6.0 | +5.5% |
| QuidelOrtho | $10.99 | +1.20% | $740.6M | — | 13.1 | 0.3 | +2.8% |
| BD | $182.91 | +1.22% | $49.79B | 54.4 | 13.8 | 2.4 | −9.6% |
| Median | 38.3 | 15.9 | 3.1 | +4.2% |